Skip to main content
SpringerLink
Log in

Plasma Urotensin II Act as a Diagnostic Biomarker for Acute Coronary Syndromes

  • Published:
International Journal of Peptide Research and Therapeutics Aims and scope Submit manuscript

Abstract

Urotensin II (U-II), one of powerful vasoconstrictor peptides, is involved in the pathogenesis of hypertension, diabetes, myocardial infarction and heart failure. However, its role in patients with acute coronary syndromes (ACS) is still unknown. We performed the present study to measure plasma U-II level in patients with ACS and the healthy subjects in the Chinese Han population. Plasma U-II level in patients with unstable angina (UA 313 ± 286 pg/dl) and acute myocardial infarction (AMI 333 ± 269 pg/dl) was higher than in healthy controls (183 ± 154 pg/dl). Plasma U-II level is positively correlated with the Gensini score (r = 0.285, P = 0.003) and Apo B level (r = 0.239, P = 0.015). Moreover, the area under the receiver operating characteristic curve for the combination of CRP and U-II was significantly higher than it for CRP (P = 0.024). We conclude that U-II, which is elevated in ACS patients, may act as a clinical non-invasive biomarker for ACS diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

Apo:

Apolipoprotein

ACS:

Acute coronary syndromes

AMI:

Acute myocardial infarction

Pro-BNP:

Pro-brain natriurtic peptide

CRP:

C reactive protein

HOMA-IR:

Homeostatic model assessment-insulin resistance

ROC:

Receiver operating characteristic

UA:

Unstable angina

U-II:

Urotensin II

UT:

Urotensin receptor

References

  • Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O (2003) The expression of urotensin II receptor (U2R) is up-regulated by interferon-γ. J Recept Signal Transduct Res 23(4):289–305

    Article  PubMed  CAS  Google Scholar 

  • Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A (2004) Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176(1):117–123

    Article  PubMed  CAS  Google Scholar 

  • Conlon JM, Yano K, Waugh D, Hazon N (1996) Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275(2–3):226–238

    Article  PubMed  CAS  Google Scholar 

  • Dai H-Y, Kang W-Q, Wang X, Yu X-J, Li Z-H, Tang M-X, Xu D-L, Li C-W, Zhang Y, Ge Z-M (2007) The involvement of transforming growth factor-β1 secretion in Urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept 140(1):88–93

    Article  PubMed  CAS  Google Scholar 

  • Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Görlach A (2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25(3):519–525

    Article  PubMed  CAS  Google Scholar 

  • Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN (2000) Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36(5):S163 &hyhen

    Article  PubMed  CAS  Google Scholar 

  • Gensini GG (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51(3):606

    Article  PubMed  CAS  Google Scholar 

  • Hassan GS, Douglas SA, Ohlstein EH, Giaid A (2005) Expression of urotensin-II in human coronary atherosclerosis. Peptides 26(12):2464–2472

    Article  PubMed  CAS  Google Scholar 

  • Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA (2004) Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370(4):238–250

    Article  PubMed  CAS  Google Scholar 

  • Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C (2006) Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease&ast. Am J Hypertens 19(5):505–510

    Article  PubMed  CAS  Google Scholar 

  • O’Gara PT, Kushner FG, Ascheim DD, DE Casey Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61(4):485–510. doi:10.1016/j.jacc.2012.11.018

    Article  PubMed  Google Scholar 

  • Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A (2005) A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 39(5):785–791

    Article  PubMed  CAS  Google Scholar 

  • Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, Tang C (2006) Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188(2):260–264

    Article  PubMed  CAS  Google Scholar 

  • Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M (2007) Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension*. Am J Hypertens 20(2):211–217

    Article  PubMed  CAS  Google Scholar 

  • Sundaram RK, Kasinathan C, Stein S, Sundaram P (2012) Novel Detox Gel Depot sequesters β-Amyloid Peptides in a mouse model of Alzheimer’s Disease. Int J Pept Res Ther 18(2):99–106

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Wang ZJ, Shi LB, Xiong ZW, Zhang LF, Meng L, Bu DF, Tang CS, Ding WH (2006) Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 27(4):858–863

    Article  PubMed  CAS  Google Scholar 

  • Watanabe T, Suguro T, Kanome T, Sakamoto Y-I, Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M, Miyazaki A (2005) Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46(4):738–744

    Article  PubMed  CAS  Google Scholar 

  • Zhu YZ, Wang ZJ, Zhu YC, Zhang L, Oakley RM, Chung CW, Lim KW, Lee HS, Ozoux ML, Linz W (2004) Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a “vasoconstrictor” with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286(3):H830–H836

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Basic Research Program of China (“973 Project” No. 2012CB517804 to Z. Yuan), the National Science Fund of China for Distinguished Young Scholars (NSFC 81025002 to Z. Yuan), and the National Natural Science Foundation of China (81100209 to Y. Wu). We thank Prof. Xu Li for technical assistance. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. This article does not contain any studies with animal subjects performed by the any of the authors.

Conflict of interest

All authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Animal studies

This article does not contain any studies with animal subjects performed by the any of the authors.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, First Affiliated Hospital of Medical School, Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, 710061, Shaanxi, China

    Prabindra Maharjan, Yue Wu, Ming He, Weiping Zhang, Xinhong Wang, Wei Xu, Xiao Liang, Juan Zhou & Zuyi Yuan

  2. Department of Gastroenterology, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, 157 West 5 Road, Xi’an, 710061, Shaanxi, China

    Pramod Shakya

Authors
  1. Prabindra Maharjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weiping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xinhong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pramod Shakya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Juan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zuyi Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zuyi Yuan.

Additional information

Prabindra Maharjan and Yue Wu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maharjan, P., Wu, Y., He, M. et al. Plasma Urotensin II Act as a Diagnostic Biomarker for Acute Coronary Syndromes. Int J Pept Res Ther 20, 145–151 (2014). https://doi.org/10.1007/s10989-013-9376-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10989-013-9376-6

Keywords

Search

Navigation